Navigation Links
The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients

- Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID and other Drugs in Newly Diagnosed Myeloma -

NORTH HOLLYWOOD, Calif., April 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said physicians should consider lowering the dose of the steroid dexamethasone when treating patients with multiple myeloma. High dose dexamethasone has been used as standard therapy for the treatment of myeloma alone and in combination with other drugs. However, interim findings from a large ongoing clinical trial of REVLIMID(R) plus dexamethasone in newly diagnosed patients, suggest lowering the "dex" dose may not only reduce side effects, but also may improve survival.

The trial, known as E4A03, is sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG). Based on these findings, ECOG has suspended further patient enrollment for this trial and has recommended that lower dose "dex" be considered for patients currently being treated on the high dose arm of the trial. Because of the public health implications, these findings are being made public immediately. The complete details will be presented at a cancer conference later this spring.

"Improved survival with low dose 'dex' and REVLIMID is an important finding because it further improves the outcome for an already successful treatment, while low dose dexamethasone is better tolerated by patients," said Brian G. M. Durie, M.D., chairman and co-founder of the International Myeloma Foundation. "We are recommending that physicians consider these findings when treating their patients across all stages of myeloma and that patients discuss these findings with their physicians."

Susie Novis, president and co-founder of
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:6/3/2015)... 3, 2015  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... treating opioid overdose with intranasal naloxone, has commenced ... (NDA) to the United States Food and Drug ... naloxone, a drug intended to treat opioid overdose. ...
(Date:6/3/2015)... BARBARA, Calif. , June 3, 2015  The ... formal endorsement of a Midwife Kit as a standard ... Kit was developed by Direct Relief in consultation with ... of charge to midwives in developing countries. ... from complications related to their pregnancy or childbirth.  Skilled ...
(Date:6/3/2015)... , June 3, 2015 ... "Interventional Cardiology & Peripheral Vascular Devices Market (Embolic ... Catheters, EVAR Stent Grafts, IVC Filters, Stents, Balloons ... MarketsandMarkets, the Interventional Cardiology and Peripheral Vascular Devices ... by 2019 with a CAGR of 7.4% from ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 2A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 3A Kit for Every Midwife: International Confederation of Midwives Endorses Direct Relief-Developed Midwife Kit as Global Standard 4The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4
(Date:6/3/2015)... “ Harmony ” was featured on NewsWatch ... at the latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... improve some aspect of their life. , A common mistake ... with difficulties in their life. However, hypnotherapy is intended for ...
(Date:6/3/2015)... June 03, 2015 On June 22, 2015, ... of genetic drug sensitivity (pharmacogenetic) testing that it has reimbursed ... as many as 19 million of the 49 million Medicare ... costly and life-threatening adverse drug events.(1) Sadly, if it became ... , Precision Medicine, the use of an individual’s genetic information ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 Dr. ... New York Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in ... appointments on weekdays to his practice. In most cases, depending ... time of the day they call, they will be seen ... “My first priority as a cardiologist is to ensure that ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 Alberto ... Award at DIA’s upcoming Annual Meeting. DIA’s Global Inspire ... leadership, level of excellence, and commitment to service on ... the Global Connector Award that annually recognizes one DIA ... has advanced the mission of DIA to foster innovation ...
(Date:6/3/2015)... Justina Molzon, MS Pharm, JD will be ... Annual Meeting. DIA’s Global Inspire Award program recognizes the ... and commitment to service on a global scale. ... Award that recognizes the “Member of the Year” who ... who has contributed to the advancement of DIA’s mission. ...
Breaking Medicine News(10 mins):Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3
... CHICAGO Results of a randomized, controlled clinical trial presented ... North America (RSNA) reveal that one in five patients with ... legs and other parts of the body also have significant ... (PAD) occurs when plaque, a combination of fat, cholesterol and ...
... St. Louis, MO, December 1, 2009 Adolescent obesity is ... every three children, resulting in 4-5 million overweight youth in ... 2009 issue of the Journal of the American Dietetic ... dietary intake and physical activity, comparing overweight adolescents who lost ...
... ... treatments and send patients home pregnant with multiples. While they want to achieve a ... mindful of the burden multiple births can put on a country’s healthcare system. , ... (PRWeb UK) November 30, 2009 -- ...
... , CHICAGO, Dec. 1 Results of a randomized, controlled ... Radiological Society of North America (RSNA) reveal that one in ... blood to the legs and other parts of the body ... Peripheral arterial disease (PAD) occurs when plaque, a combination of ...
... CHICAGO, Dec. 1 High-frequency ultrasound with elastography can ... to a study presented today at the annual meeting ... "High-frequency ultrasound with elastography has the potential to improve ... Eliot L. Siegel, M.D., vice chairman of the Department ...
... , CHICAGO, Dec. 1 A study presented ... North America (RSNA) revealed that MRI is a highly accurate ... common condition that is the leading cause of death for ... to the increase in cesarean sections and other surgeries that ...
Cached Medicine News:Health News:Severe asymptomatic heart disease may accompany narrowing in leg arteries 2Health News:Investigators identify successful weight control strategies for adolescents 2Health News:East Coast Fertility Aims to Build Families One Baby at a Time by Applying Single Embryo Transfers to Donor Egg Program 2Health News:East Coast Fertility Aims to Build Families One Baby at a Time by Applying Single Embryo Transfers to Donor Egg Program 3Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 2Health News:Severe Asymptomatic Heart Disease May Accompany Narrowing in Leg Arteries 3Health News:Special Ultrasound Accurately Identifies Skin Cancer 2Health News:Special Ultrasound Accurately Identifies Skin Cancer 3Health News:MRI Helps Detect Life-Threatening Pregnancy Complication 2Health News:MRI Helps Detect Life-Threatening Pregnancy Complication 3
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
... instrument introduction. The dual knobs allow ... and removed. The maximum diameter of ... introduced should be measured to ensure ... sterile in peel-open packages. Intended for ...
... to provide urethral drainage ... repair. The C-shape allows ... close during postoperative swelling ... maintaining urethral patency. Supplied ...
Medicine Products: